Testing a new HIV treatment in people not yet on therapy
Part of Infections clinical trials.
This trial is testing an experimental HIV pill called CL-197. It's for people with HIV who have never taken any HIV medicines before. The study lasts about 2 weeks and aims to see how the drug works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have HIV-1 and have never taken any HIV medication or HIV vaccine.
- Your CD4 count (a measure of immune health) is above 200.
- You have a healthy body weight (men at least 110 lbs, women at least 99 lbs).
- You can agree to not use other HIV drugs during the short study period.
- You are in generally good health with no serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, GS-0415, for people with HIV who are already on a stable treatment plan. It aims to see how safe and effective the new medicine is.
This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
This trial tests a new injectable treatment called LP-98 for people with HIV who have never taken HIV medications before. It aims to see if the drug is safe and can help lower the virus in your body.
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
This study tests an experimental drug called JL18008 in people with HIV who have been on stable HIV medications for years but whose immune systems (CD4 cells) haven't recovered as expected. The drug may help boost immune function in these patients.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.